February 12th 2021, 10:20pm
Clinical trials remain the gold standard when it comes to finding new treatment options for patients, particularly when it comes to renal cell carcinoma. But even if the results are positive and this combination proves to be beneficial, patients should still discuss all of their options with their oncologist to find the right sequence of treatment, says one expert.
February 12th 2021, 8:45pm
The combination of Erleada, Zytiga and the steroid prednisone was associated with a trend toward better survival outcomes in certain patients with chemotherapy-naive metastatic castration-resistant prostate cancer.
February 12th 2021, 6:30pm
Front-line treatment with Opdivo plus Cabometyx improved health-related quality of life outcomes in patients with advanced renal cell carcinoma.
February 11th 2021, 9:56pm
Patients with metastatic non–clear cell renal cell carcinoma who receive immune checkpoint inhibitor–based regimens as a first treatment option may have improved survival, versus those who receive select targeted therapies.
February 11th 2021, 8:49pm
A higher starting dose of Lenvima, compared with a lower starting dose, prolonged the time that patients with renal cell carcinoma experienced negative effects on factors including social and physical functioning, financial difficulties and cogitative functioning over time.
February 11th 2021, 6:59pm
The combination of Lenvima plus everolimus was found to be an acceptable treatment option for patients who have previously received immunotherapy for clear cell renal cell carcinoma, according to the findings of an exploratory analysis of a phase 2 trial presented virtually at the 2021 ASCO Genitourinary Cancers Symposium.
December 14th 2020, 4:00pm
More than half of the patients (66.7%) in the Venclexta and Rituxan arm who went on to receive subsequent Venclexta-based treatments experienced a partial response or partial nodal response to the therapy.
December 12th 2020, 7:00pm
Approximately half of the patients with breast cancer who failed anti-nausea or vomiting therapy for chemotherapy-induced nausea/vomiting during their first cycle of treatment failed to avoid the side effect at some point during the next three treatment cycles.
December 12th 2020, 4:00pm
Tesetaxel, a novel agent, with Xeloda contributed to a median progression-free survival of 9.8 months, compared with 6.9 months with Xeloda alone, in patients with metastatic breast cancer.
December 11th 2020, 9:30pm
An increase in gastrointestinal side effects were found with the more effective combination of oral paclitaxel and encequidar; however, new safety evaluations demonstrated that various antiemetics can help treat these effects in patients with metastatic breast cancer.
December 6th 2020, 7:30pm
The benefit observed in patients with Waldenstrom’s macroglobulinemia treated with Imbruvica (ibrutinib) plus Rituxan (rituximab), compared with placebo and Rituxan, focused on survival and response to the treatment, both of which occurred despite prior treatment and genotypes.
December 6th 2020, 7:00pm
Dr. Knight presents findings that suggest financial intervention can improve mortality rate in patients with hematologic malignancy at the 2020 ASH Meeting.
December 5th 2020, 9:33pm
Compared with patients assigned bendamustine with Rituxan, those assigned Venclexta with Rituxan maintained an overall survival benefit, with a five-year OS estimate of 82.1% for the Venclexta with Rituxan group vs. 62.2% for the bendamustine with Rituxan group.
December 5th 2020, 9:07pm
Data suggest that patients with CLL/SLL who achieve confirmed undetectable minimal residual disease following 12 cycles of Imbruvica combined with Venclexta could possibly discontinue and reasonably remain off treatment.
December 5th 2020, 8:00pm
An analysis of the phase 2 study IMbark shows how imetelstat can offer patients with high-risk myelofibrosis multiple clinical benefits, setting the stage for an expanded phase 3 trial.
December 5th 2020, 3:00pm
Five patient advocates, two oncologists and one caregiver were honored during CURE®’s eighth annual MPN Heroes Program.
December 4th 2020, 2:00pm
Evolving standards of care in newly diagnosed multiple myeloma (MM) have given patients a wider variety of possibilities but can also be disconcerting. In a presentation during CURE®’s Educated Patient® Multiple Myeloma Summit, Dr. Clifton Mo, of Dana-Farber Cancer Institute, explores the treatment landscape and breaks down what these different options can offer patients.
November 11th 2020, 7:00pm
CAR-T cell therapy is a relatively new treatment option for patients with blood cancers, but it’s one showing promise across the landscape. Here’s what you need to know.
October 20th 2020, 8:00pm
View the entire Extraordinary Healer® Award for Oncology Nursing virtual presentation here!
June 22nd 2020, 9:08pm
In partnership with CURE®, Susan G. Komen Greater New York City hosts its 4th Annual Patient Navigation Town Hall "Empowering and Mobilizing Our Patient Navigation Workforce". Oncologists, community health workers and patient navigators will get together on June 23rd, via webinar, to discuss the impact of the COVID-19 pandemic on the cancer landscape and how professionals and patients can navigate the fallout moving forward.
March 28th 2020, 1:00am
“Often you think we’re the victim, but there’s a lot that you can do to be your own advocate and participate in your healing,” says stage four metastatic breast cancer thriver Nalie Agustin.
March 24th 2020, 7:06pm
Genetic testing offers a care team a wealth of knowledge to help them craft treatments, but it also can help match patients to clinical trials for potentially better outcomes.
March 24th 2020, 12:15am
Patients faced with cancer are also faced with tough uphill financial battles, but there are assistance programs that can help.
March 21st 2020, 12:00am
Having the right understanding and information of a patient’s genetics can not only help treat cancer but also help prevent it.
March 20th 2020, 12:00am
Understanding a diagnosis is not just something for a patient's care team, the patient needs to understand their diagnosis as well.
March 19th 2020, 1:09am
Understanding biomarkers specific to breast cancer can guide treatment plans and help families with a history of the disease take preventive measures.
March 18th 2020, 10:00pm
As CDK 4/6 inhibitors become a bigger part of the treatment of breast cancer, CURE® sat down with clinical nurse specialist Patricia Jakel to discuss the essentials about the drug.
March 14th 2020, 10:00pm
Don’t be worried to get a second opinion — it could save your life.
March 13th 2020, 10:27pm
Being a patient with cancer gives you a unique perspective that can become beneficial when serving as an advocate for others.
March 9th 2020, 10:02pm
If patients take a deep breath and concentrate on the journey ahead after receiving a diagnosis, they can find a path forward, says one metastatic breast cancer thriver.